Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a biotechnology company that publicly describes its focus as the development of emavusertib (CA-4948), an orally available small molecule inhibitor of IRAK4 and, in some disclosures, FLT3. The Curis news stream highlights clinical progress, financing events, and corporate updates that shape the company’s development plans and capital position.
News about Curis frequently covers clinical data and study milestones for emavusertib. The company has reported interim results from its frontline AML triplet study (emavusertib with venetoclax and azacitidine), updates from the TakeAim Lymphoma and TakeAim Leukemia Phase 1/2 trials in PCNSL, AML and high-risk MDS, and presentations at major medical meetings such as the American Society of Hematology (ASH), the Society for Neuro-Oncology (SNO), and ASCO. These releases often describe response measures such as minimal residual disease status and safety observations within defined patient cohorts.
Investors following CRIS news will also see financing and capital markets announcements, including registered direct offerings, concurrent private placements of pre-funded and common warrants, and a PIPE financing involving Series B convertible preferred stock and multiple warrant series. Curis’s news has detailed the structure of these transactions, the gross proceeds, and the stated use of funds for research and development, general corporate purposes, and working capital.
Additional news items address corporate and regulatory developments, such as business updates, quarterly financial results, inducement equity grants, conference participation, and Nasdaq listing compliance notices related to market value of listed securities requirements. For readers tracking Curis, the CRIS news page provides an organized view of these clinical, financial, and listing-related disclosures in one place, allowing users to review how trial data, capital raises, and regulatory interactions evolve over time.
Curis, Inc. (NASDAQ: CRIS) reported its third-quarter 2022 business update, focusing on the development of emavusertib for relapsed or refractory acute myeloid leukemia. The company will present additional data at ASH 2022, highlighting a total of 24 patients treated. Curis plans to concentrate resources on emavusertib, reducing its workforce by approximately 30% and extending its cash runway into 2025. Financially, Curis reported a net loss of $13.3 million for Q3 2022, with net revenues of $2.8 million. Cash and investments totaled $98.7 million as of September 30, 2022.
Curis, Inc. (NASDAQ: CRIS) announced its participation in the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022) in Boston, showcasing three significant research posters. Key highlights include a presentation on emavusertib, an IRAK4 inhibitor, detailing its therapeutic potential for melanoma brain metastases. Additionally, two presentations on CI-8993, an anti-VISTA antibody, focus on its pharmacokinetic and pharmacodynamic profiles. These presentations aim to enhance understanding of their roles in cancer treatment.
Curis, Inc. (NASDAQ: CRIS) plans to report its third quarter 2022 financial results on November 9, 2022, after U.S. market closure. Following the release, management will host a conference call at 4:30 p.m. ET to discuss the results. Curis is known for developing innovative cancer therapeutics, including collaborations on various immuno-oncology projects. Notably, the TakeAim Leukemia trial of emavusertib is on a partial clinical hold, impacting new patient enrollment.
On October 3, 2022, Curis, Inc. (NASDAQ: CRIS) announced the approval of inducement stock options for 121,650 shares to two new employees. These options have an exercise price equal to the stock's closing price on that date, a 10-year term, and vest over four years. This grant was made outside of the company's existing stock incentive plan as a material inducement for employment. Curis specializes in innovative cancer therapeutics, including partnerships for developing novel treatments like emavusertib, currently in clinical trials for hematologic malignancies.
Curis, Inc. (NASDAQ: CRIS) will host the 1st Symposium on IRAK4 in Cancer on October 7, 2022, from 9:00 am to 1:00 pm ET. The virtual event, led by renowned experts, will explore the role of IRAK4, a promising target for cancer treatment, particularly in hematologic malignancies. CEO James Dentzer emphasized IRAK4's potential as an immunotherapy target. The agenda includes discussions on IRAK4 biology, mechanisms in cancer, and therapeutic strategies involving IRAK4 inhibitors.
Curis, Inc. (NASDAQ: CRIS) has announced the 2nd Annual VISTA Symposium, scheduled for September 23, 2022, from 9:00 am to 1:00 pm ET, focusing on VISTA in cancer treatment. Hosted by Dr. Randolph Noelle, the symposium will feature discussions on VISTA biology, immune evasion, and therapeutic strategies. CEO James Dentzer emphasized Curis's leading role in VISTA research, highlighting progress with their program CI-8993. The event will bring together global experts to advance understanding and treatment options for cancer patients.
Curis, a biotechnology company focused on cancer therapeutics, announced that CEO James Dentzer will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 4:00 p.m. ET in New York, NY. He will also attend the Cantor Oncology and HemOnc Conference on September 28, 2022, at 3:25 p.m. ET. A webcast of the H.C. Wainwright presentation will be available on the Curis website for 90 days post-event. Curis is developing innovative cancer therapies, including emavusertib, currently in clinical trials.
Curis, Inc. (NASDAQ: CRIS) announced the FDA's approval to resume patient enrollment in the monotherapy phase of its TakeAim Leukemia study. Previously, this study faced a partial hold that the FDA imposed in April 2022 due to safety concerns related to rhabdomyolysis. After reviewing additional data, the FDA allowed Curis to enroll at least nine new patients at the 200mg dose level, while the hold remains for the combination and expansion phases. Curis also projects preliminary clinical data availability in 2023 as it works alongside the FDA on clinical plans for emavusertib.
Curis, Inc. (NASDAQ: CRIS) announced the U.S. FDA lifted the partial clinical hold on its TakeAim Lymphoma Phase 1/2 study of emavusertib. Following the FDA's review, Curis is preparing to resume patient enrollment in Q3 2022. The hold was lifted after agreement on the strategy for managing rhabdomyolysis. Curis will provide a preliminary clinical data update in 2023. The TakeAim Lymphoma study explores emavusertib's effectiveness in treating hematologic malignancies, while the TakeAim Leukemia study remains on hold since April 2022.
Curis, Inc. (CRIS) reported promising clinical results for emavusertib and ibrutinib at ASCO 2022, showing tumor reduction in 8 of 9 evaluable patients, highlighting potential in overcoming ibrutinib resistance. The company appointed Diantha Duvall as CFO, bringing extensive industry experience. For Q2 2022, Curis recorded a net loss of $15.9 million ($0.17/share), a rise from a $10.8 million loss in Q2 2021. Revenue remained stable at $2.4 million. With a strong balance sheet of $107.2 million, Curis is funded into 2024. A conference call is scheduled for today to discuss these results.